QIAGEN Expands Supervisory Board With Appointment of a New Member
- Thomas Ebeling appointed to the Supervisory Board
VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today the appointment of Thomas Ebeling, a leading international executive with extensive experience in the healthcare, media and consumer goods industries, as a member of the Supervisory Board with immediate effect.
Mr. Ebeling joins QIAGEN as part of a process launched by the Supervisory Board in 2020 to further complement and enhance the Board’s already extensive experience in Life Sciences and diagnostics. The addition of Mr. Ebeling brings the number of current Supervisory Board members to eight.
“On behalf of the Supervisory Board and Managing Board, I would like to welcome Thomas Ebeling to QIAGEN. This appointment further deepens our expertise and experience in many ways, in particular given his international background in healthcare and extensive experience in general management,” said Lawrence Rosen, Chairman of the Supervisory Board. “As we continue the review process initiated in 2020, the Supervisory Board continues to pursue the highest level of excellence in corporate governance and support of the management team to create value for QIAGEN’s stakeholders, including its shareholders.”
Mr. Ebeling has been an advisor in recent years to various businesses after having served as the CEO of the publicly-listed German media group ProSiebenSat.1 Media from 2009 to 2018. Prior to that, he worked for the global healthcare company Novartis from 1997 to 2008, including roles as CEO of Novartis Pharmaceuticals and also as CEO of Novartis Consumer Health. He began his career in 1987 and held various positions in marketing and sales in the consumer goods industry before joining Novartis. Mr. Ebeling, who has a degree in psychology from the University of Hamburg, has previously served on the Supervisory Boards of Bayer AG and Lonza AG.
Please find the full press release here.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005852/en/
John Gilardi
Vice President Corporate Communications and Investor Relations
+49 2103 29 1171 and +49 152 018 11711 and +1 240 686 2222 / [email protected]
Phoebe Loh
Director Investor Relations
+49 2103 29 11457 / [email protected]
Dr. Thomas Theuringer
Senior Director, Head of External Communications
+49 2103 29 11826 / [email protected]
Robert Reitze
Senior Manager Public Relations
+49 2103 29 11676 / [email protected]
Source: QIAGEN
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kopin Exhibiting at SPIE Defense & Commercial Sensing Conference at the National Harbor, MD April 23 through April 25, 2024
- ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages The Chemours Company Investors to Secure Counsel Before Important Deadline in Securities Class Action – CC
- WellSpan Health Breaks Ground on New Shrewsbury Hospital That Will Improve Access to Care Close to Home
Create E-mail Alert Related Categories
Business Wire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!